Basic information Safety Supplier Related

LMT-28

Basic information Safety Supplier Related

LMT-28 Basic information

Product Name:
LMT-28
Synonyms:
  • LMT-28
  • 2-Oxazolidinone, 3-[(2S,3S)-3-hydroxy-2-methyl-4-methylene-1-oxononyl]-4-(1-methylethyl)-, (4S)-
  • LMT-28 >=98% (HPLC)
  • LMT28,LMT 28
  • LMT-28, 10 mM in DMSO
  • (S)-3-((2S,3S)-3-Hydroxy-2-methyl-4-methylenenonanoyl)-4-isopropyloxazolidin-2-one
CAS:
1239600-18-0
MF:
C17H29NO4
MW:
311.42
Mol File:
1239600-18-0.mol
More
Less

LMT-28 Chemical Properties

Boiling point:
452.9±38.0 °C(Predicted)
Density 
1.065±0.06 g/cm3(Predicted)
storage temp. 
-20°C
solubility 
100 mg/mL in DMSO (321.11 mM),
pka
13.97±0.20(Predicted)
form 
oil
color 
colorless to light yellow, oil
Water Solubility 
< 0.1 mg/mL Water (insoluble)
More
Less

LMT-28 Usage And Synthesis

Uses

LMT-28 is an orally active and the first synthetic IL-6 inhibitor that functions through direct binding to gp130. LMT-28 shows low toxicity and selectively inhibits IL-6-induced phosphorylation of STAT3, JAK2, and gp130[1].

Biochem/physiol Actions

LMT-28 is a derivative of oxazolidinone. It has the ability to repress the activation of signal transducer and activator of transcription 3 (STAT3) stimulated by interleukin 6 (IL-6). Orally administered LMT-28 reduced arthritis and acute pancreatitis stimulated by collagen in mice pathologic models.

in vivo

LMT-28 (0-0.5 mg/kg; p.o.; once daily for 15 days) alleviates CIA in mice[1].
LMT-28 (0.25 or 1 mg/kg; p.o.) ameliorates the progression of pancreatitis in mice. LMT-28 binds directly and specifically to gp130, and thereby inhibits the interaction of gp130 with the IL-6/IL-6Rα complex[1].

Animal Model:Six-week-old male DBA/1J mice (collagen-induced arthritis mice, CIA)[1]
Dosage:0-0.5 mg/kg
Administration:Oral; once daily for 15 days
Result:Markedly reduced the serum levels of cartilage oligomeric matrix protein (COMP) by 50%, serum amyloid P (SAP) by 55%, and anti-CII IgG by 62%.

IC 50

IL-6

References

[1] Hong SS, et al. A Novel Small-Molecule Inhibitor Targeting the IL-6 Receptor β Subunit, Glycoprotein 130. J Immunol. 2015 Jul 1;195(1):237-45. DOI:10.4049/jimmunol.1402908

LMT-28Supplier

Nanjing Chemlin Chemical Co., Ltd
Tel
025-83697070
Email
info@chemlin.com.cn
Bide Pharmatech Ltd.
Tel
400-164-7117 13681763483
Email
product02@bidepharm.com
Sigma-Aldrich
Tel
021-61415566 800-8193336
Email
orderCN@merckgroup.com
Shanghai EFE Biological Technology Co., Ltd.
Tel
021-65675885 18964387627
Email
info@efebio.com
Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com